A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America, according to the announcement the European Society of Medical Oncology (ESMO) has done today.
The contribution of patients and patient experts provides tangible value to other stakeholders and society that should be fairly compensated. Currently, there is no transparent and consistent system for financial compensation in place that reflects the level of individual contribution and expertise.
At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020 CARAMBA project. MPE is collaborating with a consortium of European partners, including the University of Würzburg, on CARAMBA which is…
Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects.
Today marks the official launch of a new international project consortium, known as “CARAMBA”, which will research an innovative immunotherapy for the treatment of multiple myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide-range of stakeholders, the consortium aims to ensure the streamlined transition of CAR-T from the laboratory…
MPE is inviting members to express their interest in participating in a small pilot on patient information for newly diagnosed myeloma patients. As part of this pilot, MPE will be adapting and translating an Infopack for newly diagnosed patients (created by Myeloma UK) for use in small group of European countries. The Infopack provides information…
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2017. The talk will be given by Dr María Victoria Mateos, Associate Professor of Hematology and Consultant.…
The 59th American Society of Hematology (ASH) Annual Meeting will take place from 9 – 12 December in Atlanta, Georgia, United States (US). Myeloma Patients Europe (MPE) will be attending the meeting, alongside thousands of leading doctors, researchers and patient advocates in the field of blood cancer (hematology). Below we explain ASH and the importance…
